![Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study - Kirschbrown - 2019 - The Journal of Clinical Pharmacology - Wiley Online Library Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study - Kirschbrown - 2019 - The Journal of Clinical Pharmacology - Wiley Online Library](https://accp1.onlinelibrary.wiley.com/cms/asset/ddf2e90e-908d-4e23-b57e-8209658c8a9a/jcph1362-fig-0001-m.jpg)
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study - Kirschbrown - 2019 - The Journal of Clinical Pharmacology - Wiley Online Library
![Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41523-021-00284-y/MediaObjects/41523_2021_284_Fig1_HTML.png)
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
![Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction | Journal of the American Heart Association Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/37ddafcd-e3e8-43da-8895-c46f4bddef9f/jah33313-fig-0001.png)
Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction | Journal of the American Heart Association
![6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet](https://www.thelancet.com/cms/attachment/e961d20e-ceaa-45ca-9a0e-9dcf5ad06ffe/gr1.gif)